This myositis specific autoAb has been associated with digital gangrene in patients with dermatomyositis
What is MDA5?
#ACR26 #KnowledgeBowl
What is MDA5?
#ACR26 #KnowledgeBowl
November 8, 2026 at 6:53 PM
This myositis specific autoAb has been associated with digital gangrene in patients with dermatomyositis
What is MDA5?
#ACR26 #KnowledgeBowl
What is MDA5?
#ACR26 #KnowledgeBowl
#ACR26 Epic Cosmos abstracts
⭐ Abs 0824 Saksena/Penn
🔎 Dermatomyositis and rural/urban prevalence
👉️ Looks like a rural predominance for dermatomyositis diagnoses; need to look into this with more granularity
⭐ Abs 0824 Saksena/Penn
🔎 Dermatomyositis and rural/urban prevalence
👉️ Looks like a rural predominance for dermatomyositis diagnoses; need to look into this with more granularity
November 7, 2026 at 5:04 PM
#ACR26 Epic Cosmos abstracts
⭐ Abs 0824 Saksena/Penn
🔎 Dermatomyositis and rural/urban prevalence
👉️ Looks like a rural predominance for dermatomyositis diagnoses; need to look into this with more granularity
⭐ Abs 0824 Saksena/Penn
🔎 Dermatomyositis and rural/urban prevalence
👉️ Looks like a rural predominance for dermatomyositis diagnoses; need to look into this with more granularity
This oral medication demonstrated efficacy in dermatomyositis in a phase 3 trial in 2025
What is brepocitinib?
#ACR26 #KnowledgeBowl
What is brepocitinib?
#ACR26 #KnowledgeBowl
November 8, 2026 at 6:29 PM
This oral medication demonstrated efficacy in dermatomyositis in a phase 3 trial in 2025
What is brepocitinib?
#ACR26 #KnowledgeBowl
What is brepocitinib?
#ACR26 #KnowledgeBowl
A paper using RRID:AB_2572996 from @thermofishersci.bsky.social was just published in iScience. We value the author's support of reproducibility. #accelerateopenscience #BetterScience #ReproducibleResearch
Spatial transcriptomic mapping of anti-MDA5 dermatomyositis reveals perivascular enrichment of type I interferon responses and immune activation
Read the full paper: Spatial transcriptomic mapping of anti-MDA5 dermatomyositis reveals perivascular enrichment of type I interferon responses and immune activation
doi.org
November 7, 2026 at 8:00 AM
A paper using RRID:AB_2572996 from @thermofishersci.bsky.social was just published in iScience. We value the author's support of reproducibility. #accelerateopenscience #BetterScience #ReproducibleResearch
This Behind the Paper blog from the Journal of Medical Case Reports uses a real-world case to illustrate how evolving physiology may become clinically important before the full diagnostic criteria for a given syndrome are satisfied.
#MedSky
#MedSky
JMCR: Clinical Reasoning from Case Reports
When Cytopenia Changes the Diagnosis: Anti-MDA5 Dermatomyositis, Rapidly Progressive Interstitial Lung Disease, and Macrophage Activation
bit.ly
November 1, 2026 at 8:45 PM
This Behind the Paper blog from the Journal of Medical Case Reports uses a real-world case to illustrate how evolving physiology may become clinically important before the full diagnostic criteria for a given syndrome are satisfied.
#MedSky
#MedSky
⭐ Dermatomyositis - Brepocitinib - Vleugels NEJM
Phase 3 trial, PO TYK2-JAK1 inhibitor
1* outcome: Total Improvement Score (0-100) at week 52
FDA approved August 27th but with infx black box warnings
#ACR26
Phase 3 trial, PO TYK2-JAK1 inhibitor
1* outcome: Total Improvement Score (0-100) at week 52
FDA approved August 27th but with infx black box warnings
#ACR26
November 8, 2026 at 1:00 PM
⭐ Dermatomyositis - Brepocitinib - Vleugels NEJM
Phase 3 trial, PO TYK2-JAK1 inhibitor
1* outcome: Total Improvement Score (0-100) at week 52
FDA approved August 27th but with infx black box warnings
#ACR26
Phase 3 trial, PO TYK2-JAK1 inhibitor
1* outcome: Total Improvement Score (0-100) at week 52
FDA approved August 27th but with infx black box warnings
#ACR26
✨@londyloo.bsky.social is paving the way by exploring what Epic Cosmos can do for rheum research
MDA5+ positivity and what it means
acrabstracts.org/abstract/bey...
#ACR26
MDA5+ positivity and what it means
acrabstracts.org/abstract/bey...
#ACR26
Beyond Anti-MDA5 Dermatomyositis: Clinical Spectrum, ILD Burden, and Mortality Among 2,489 Anti-MDA5-Positive Adults - ACR Meeting Abstracts
Background/Purpose: Anti-MDA5 positivity is rare and associated with dermatomyositis-spectrum disease, interstitial lung disease (ILD), and increased mortality. Most published studies are limited to <...
acrabstracts.org
October 31, 2026 at 1:15 PM
✨@londyloo.bsky.social is paving the way by exploring what Epic Cosmos can do for rheum research
MDA5+ positivity and what it means
acrabstracts.org/abstract/bey...
#ACR26
MDA5+ positivity and what it means
acrabstracts.org/abstract/bey...
#ACR26
She lost strength in her diaphragm because she had a soft-tissues disease call dermatomyositis which effect muscles in the entire body as well as vocal function. Furthermore, the treatment of that disease in the 1950s when she was diagnosed was daily Prednisone which EXTREMELY damages the voice.
October 26, 2026 at 1:21 PM
She lost strength in her diaphragm because she had a soft-tissues disease call dermatomyositis which effect muscles in the entire body as well as vocal function. Furthermore, the treatment of that disease in the 1950s when she was diagnosed was daily Prednisone which EXTREMELY damages the voice.
Adult Dermatomyositis is a rare autoimmune disease causing distinctive skin rashes and muscle weakness. In 2026, the FDA approved brepocitinib, the first oral targeted therapy for DM.
Learn more: https://www.myositis.org
You may be rare, but you're not alone!
#rareDisease #rareDiseaseAwareness
Learn more: https://www.myositis.org
You may be rare, but you're not alone!
#rareDisease #rareDiseaseAwareness
October 26, 2026 at 2:00 PM
Adult Dermatomyositis is a rare autoimmune disease causing distinctive skin rashes and muscle weakness. In 2026, the FDA approved brepocitinib, the first oral targeted therapy for DM.
Learn more: https://www.myositis.org
You may be rare, but you're not alone!
#rareDisease #rareDiseaseAwareness
Learn more: https://www.myositis.org
You may be rare, but you're not alone!
#rareDisease #rareDiseaseAwareness
Advancing CD38 from a marker of disease activity to an active regulator of interferon responses in juvenile dermatomyositis https://www.biorxiv.org/content/10.64898/2026.10.14.758964v1
October 21, 2026 at 12:15 AM
Advancing CD38 from a marker of disease activity to an active regulator of interferon responses in juvenile dermatomyositis https://www.biorxiv.org/content/10.64898/2026.10.14.758964v1
https:/https://www.linkedin.com/pulse/dermatomyositis-market-global-outlook-us-japan-korea-europe-azkgf/www.linkedin.com/pulse/dermatomyositis-market-global-outlook-us-japan-korea-europe-azkgf
Dermatomyositis Market: Global Outlook with US, Japan, Korea, Europe Insights
The Dermatomyositis Market was valued at USD 1.2 billion in 2025 and is poised to grow from USD 1.
www.linkedin.com
October 20, 2026 at 12:10 PM
https:/https://www.linkedin.com/pulse/dermatomyositis-market-global-outlook-us-japan-korea-europe-azkgf/www.linkedin.com/pulse/dermatomyositis-market-global-outlook-us-japan-korea-europe-azkgf
Advancing CD38 from a marker of disease activity to an active regulator of interferon responses in juvenile dermatomyositis https://www.biorxiv.org/content/10.64898/2026.10.14.758964v1
October 21, 2026 at 12:15 AM
Advancing CD38 from a marker of disease activity to an active regulator of interferon responses in juvenile dermatomyositis https://www.biorxiv.org/content/10.64898/2026.10.14.758964v1
Dermatomyositis y'all!
I would put money on it! Gottron's papules are very clear on his hands. Thos are pathognomonic for DM. Explains his waddling gate too. The ruddiness and puffy skin over the knuckles is also on the other hand.
That's my unprofessional opinion 😜
I would put money on it! Gottron's papules are very clear on his hands. Thos are pathognomonic for DM. Explains his waddling gate too. The ruddiness and puffy skin over the knuckles is also on the other hand.
That's my unprofessional opinion 😜
October 19, 2026 at 11:11 PM
Dermatomyositis y'all!
I would put money on it! Gottron's papules are very clear on his hands. Thos are pathognomonic for DM. Explains his waddling gate too. The ruddiness and puffy skin over the knuckles is also on the other hand.
That's my unprofessional opinion 😜
I would put money on it! Gottron's papules are very clear on his hands. Thos are pathognomonic for DM. Explains his waddling gate too. The ruddiness and puffy skin over the knuckles is also on the other hand.
That's my unprofessional opinion 😜
Research Article
Long-Term Safety and Efficacy of Dazukibart in Dermatomyositis: Combined Phase II Results From Double-Blind and Open-Label Extension Studies
📖 doi.org/10.3899/jrhe...
@harvardmed.bsky.social @stanford.edu
#Dermatomyositis
Long-Term Safety and Efficacy of Dazukibart in Dermatomyositis: Combined Phase II Results From Double-Blind and Open-Label Extension Studies
📖 doi.org/10.3899/jrhe...
@harvardmed.bsky.social @stanford.edu
#Dermatomyositis
October 13, 2026 at 2:46 PM
Research Article
Long-Term Safety and Efficacy of Dazukibart in Dermatomyositis: Combined Phase II Results From Double-Blind and Open-Label Extension Studies
📖 doi.org/10.3899/jrhe...
@harvardmed.bsky.social @stanford.edu
#Dermatomyositis
Long-Term Safety and Efficacy of Dazukibart in Dermatomyositis: Combined Phase II Results From Double-Blind and Open-Label Extension Studies
📖 doi.org/10.3899/jrhe...
@harvardmed.bsky.social @stanford.edu
#Dermatomyositis
After years of inactivity, therapeutic development for dermatomyositis has begun to move forward with several new therapies and therapeutic strategies.
Read more at: https://www.medpagetoday.com/dermatology/generaldermatology/123347
Read more at: https://www.medpagetoday.com/dermatology/generaldermatology/123347
Treatment Landscape for Dermatomyositis Is Evolving
Recent approvals, ongoing trials offer encouragement
www.medpagetoday.com
October 13, 2026 at 2:57 AM
After years of inactivity, therapeutic development for dermatomyositis has begun to move forward with several new therapies and therapeutic strategies.
Read more at: https://www.medpagetoday.com/dermatology/generaldermatology/123347
Read more at: https://www.medpagetoday.com/dermatology/generaldermatology/123347
On Aug 27, 2026 the FDA approved Lisraya (brepocitinib), the first oral drug ever cleared for dermatomyositis. It blocks JAK and TYK2, the relay carrying that interferon signal. In a 52-week trial of 241 adults it beat placebo.
October 8, 2026 at 1:00 PM
On Aug 27, 2026 the FDA approved Lisraya (brepocitinib), the first oral drug ever cleared for dermatomyositis. It blocks JAK and TYK2, the relay carrying that interferon signal. In a 52-week trial of 241 adults it beat placebo.
Most autoimmune diseases go after one tissue. Dermatomyositis goes after two, the skin and the muscle, and it damages the same thing in both: the smallest blood vessels running through them. Last week it got its first pill. 🧵
October 8, 2026 at 1:00 PM
Most autoimmune diseases go after one tissue. Dermatomyositis goes after two, the skin and the muscle, and it damages the same thing in both: the smallest blood vessels running through them. Last week it got its first pill. 🧵
Brepocitinib in patients with #dermatomyositis was associated with improvements in cutaneous disease activity, #pruritus, and skin-related quality of life through 52 weeks.
https://www.dermatologyadvisor.com/news/brepocitinib-effective-improving-cutaneous-activity-dermatomyositis/
https://www.dermatologyadvisor.com/news/brepocitinib-effective-improving-cutaneous-activity-dermatomyositis/
Brepocitinib Is Effective for Improving Cutaneous Activity in Dermatomyositis
Brepocitinib 30 mg is more effective than placebo for skin-specific outcomes through 52 weeks of treatment among patients with dermatomyositis.
www.dermatologyadvisor.com
October 5, 2026 at 8:00 PM
Brepocitinib in patients with #dermatomyositis was associated with improvements in cutaneous disease activity, #pruritus, and skin-related quality of life through 52 weeks.
https://www.dermatologyadvisor.com/news/brepocitinib-effective-improving-cutaneous-activity-dermatomyositis/
https://www.dermatologyadvisor.com/news/brepocitinib-effective-improving-cutaneous-activity-dermatomyositis/
I love that my rheumatologist just does the bare minimum.
"Teah you have symptoms of dermatomyositis and SLE but I'm not really going to do anything other than repeat standard blood tests in 6 months and keep you on hydroxychloroquine. Bye."
Like thanks dude. Really reassuring.
"Teah you have symptoms of dermatomyositis and SLE but I'm not really going to do anything other than repeat standard blood tests in 6 months and keep you on hydroxychloroquine. Bye."
Like thanks dude. Really reassuring.
October 3, 2026 at 11:45 PM
I love that my rheumatologist just does the bare minimum.
"Teah you have symptoms of dermatomyositis and SLE but I'm not really going to do anything other than repeat standard blood tests in 6 months and keep you on hydroxychloroquine. Bye."
Like thanks dude. Really reassuring.
"Teah you have symptoms of dermatomyositis and SLE but I'm not really going to do anything other than repeat standard blood tests in 6 months and keep you on hydroxychloroquine. Bye."
Like thanks dude. Really reassuring.
Especially because it's looking very likely I have dermatomyositis and proper treatment of it with IVIG could prevent it from becoming a full blown disease but nooo let's just sit and do fucking nothing until I develop organ involvement and get worse lol.
October 3, 2026 at 11:52 PM
Especially because it's looking very likely I have dermatomyositis and proper treatment of it with IVIG could prevent it from becoming a full blown disease but nooo let's just sit and do fucking nothing until I develop organ involvement and get worse lol.
RRIDs were included in this in Scientific Reports paper. Thanks for making your methods matter! #methodsmatter #accelerateopenscience #RRID
Engineered pediatric human muscle models the interferon-driven transcriptome of juvenile dermatomyositis - Scientific Reports
Read the full paper: Engineered pediatric human muscle models the interferon-driven transcriptome of juvenile dermatomyositis
doi.org
October 3, 2026 at 7:00 AM
RRIDs were included in this in Scientific Reports paper. Thanks for making your methods matter! #methodsmatter #accelerateopenscience #RRID
🚨 $JBIO
On September 30, 2026, Jade Biosciences, Inc. announced preclinical data characterizing JADE301, its anti-interferon beta monoclonal antibody in development for dermatomyositis , a rare, chronic and debilitating autoimmune disease characterized by painful inflammatory skin disease and pro...
On September 30, 2026, Jade Biosciences, Inc. announced preclinical data characterizing JADE301, its anti-interferon beta monoclonal antibody in development for dermatomyositis , a rare, chronic and debilitating autoimmune disease characterized by painful inflammatory skin disease and pro...
SEC Filing: JBIO
Click to view the official SEC document.
www.sec.gov
September 30, 2026 at 11:14 AM
🚨 $JBIO
On September 30, 2026, Jade Biosciences, Inc. announced preclinical data characterizing JADE301, its anti-interferon beta monoclonal antibody in development for dermatomyositis , a rare, chronic and debilitating autoimmune disease characterized by painful inflammatory skin disease and pro...
On September 30, 2026, Jade Biosciences, Inc. announced preclinical data characterizing JADE301, its anti-interferon beta monoclonal antibody in development for dermatomyositis , a rare, chronic and debilitating autoimmune disease characterized by painful inflammatory skin disease and pro...
Retrospective study from India on 157 juvenile dermatomyositis (JDM) pts - 44 (28%) had calcinosis. They had a long Dx delay (12 mos), were NXP2+ in 41%, & high risk for Lipodystrophy (39% vs 5%). 39% improved while 61% had static/progressive Dz buff.ly/sYUD9kU
Catching up with calcinosis: analysis of clinical characteristics, myositis-specific autoantibodies, and response to therapy in juvenile dermatomyositis
Paediatric Rheumatology; Authors: P. Vignesh, R. Aggarwal, A. Sil, S. Basu, S. Mondal, A. Dod, V. Keshavamurthy, M. Dhaliwal, S. Sharma, R.K. Pilania, A.K. Jindal, D. Suri, A. Rawat, S. Singh
buff.ly
September 29, 2026 at 2:01 PM
Retrospective study from India on 157 juvenile dermatomyositis (JDM) pts - 44 (28%) had calcinosis. They had a long Dx delay (12 mos), were NXP2+ in 41%, & high risk for Lipodystrophy (39% vs 5%). 39% improved while 61% had static/progressive Dz buff.ly/sYUD9kU